文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SCHISTOACT:吡喹酮联合青蒿素类复方治疗曼氏血吸虫感染疗效与安全性的开放标签、五臂、非劣效性、个体随机对照试验方案

SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection.
PubMed 文献 · Trials · 2023-11-27

SCHISTOACT研究旨在评估吡喹酮联合四种青蒿素类复方治疗肯尼亚曼氏血吸虫感染的疗效与安全性。该开放标签、五臂、非劣效性、个体随机对照试验纳入540名来自肯尼亚中部基里尼亚加郡Mwea地区、经Kato-Katz法诊断的曼氏血吸虫感染学龄儿童,按1:1:1:1:1随机分配至吡喹酮单剂联合3天疗程的青蒿琥酯-磺胺多辛/乙胺嘧啶、青蒿琥酯-阿莫地喹、青蒿琥酯联合甲氟喹、双氢青蒿素-哌喹或吡喹酮对照臂,随访12周,主要终点为治疗6周后的治愈率(显微镜评估)和安全性(不良事件)。

要点

  • SCHISTOACT研究比较吡喹酮联合四种青蒿素类复方与吡喹酮单药治疗曼氏血吸虫感染的疗效与安全性。
  • 研究纳入540名肯尼亚曼氏血吸虫感染学龄儿童,随机分为五臂,随访12周。
  • 主要终点为治疗6周后的治愈率和不良事件,非劣效性界值为治愈率风险差的-10。

核心结论

  • SCHISTOACT研究旨在评估吡喹酮联合四种青蒿素类复方治疗曼氏血吸虫感染的疗效与安全性,并检验非劣效性假设。
  • 该研究评估将青蒿素类复方疗法(ACTs)重新用于治疗血吸虫病的策略,并加强当地开展被忽视热带病干预临床试验的能力。

研究设计与样本

  • SCHISTOACT研究为开放标签、头对头、五臂、概念验证、非劣效性、个体随机对照试验,随访12周。
  • 研究纳入540名来自肯尼亚中部基里尼亚加郡Mwea地区、经Kato-Katz法诊断的曼氏血吸虫感染学龄儿童,按1:1:1:1:1随机分配至五个治疗臂。

主要发现

  • 五个治疗臂分别为:吡喹酮单剂联合3天疗程的青蒿琥酯-磺胺多辛/乙胺嘧啶、青蒿琥酯-阿莫地喹、青蒿琥酯联合甲氟喹、双氢青蒿素-哌喹,以及吡喹酮对照臂。
  • 主要终点为治疗6周后各研究臂的疗效(治愈率,显微镜评估)和安全性(不良事件)。
  • 次要终点包括治疗12周后的累积治愈率、虫卵减少率和再感染率。
  • 非劣效性界值设定为吡喹酮与联合治疗之间治愈率风险差的-10。

关键数值与推荐

  • 非劣效性界值为吡喹酮与联合治疗之间治愈率风险差的-10。
  • 主要终点为治疗6周后的治愈率(显微镜评估)和不良事件。
  • 次要终点包括治疗12周后的累积治愈率、虫卵减少率和再感染率。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schistosomiasis control relies on praziquantel for preventive chemotherapy. Alternative drugs are needed for the treatment and control of schistosomiasis. Praziquantel is effective against adult schistosome worms but ineffective against larval stages of the parasite and cannot prevent re-infection or interrupt the transmission of infection. Continued reliance on praziquantel for wide-scale schistosomiasis control will likely accelerate the emergence of drug resistance. Artemisinin derivatives are effective against the juvenile stages but ineffective against adult worms. The SCHISTOACT study aimed to evaluate the efficacy and safety of praziquantel plus one of four artemisinin-based combinations in treating Schistosoma mansoni infection in Kenya. METHODS: The SCHISTOACT study is an open-label, head-to-head, five-arm, proof-of-concept, non-inferiority, individually randomized controlled trial with a follow-up of 12 weeks. A total of 540 primary school-aged children from the Mwea area, Kirinyaga County in central Kenya, diagnosed with S. mansoni infection (by Kato-Katz method) are randomly allocated (1:1:1:1:1) to a single dose of praziquantel plus a 3-day course of artesunate-sulfalene/pyrimethamine, or artesunate-amodiaquine, or artesunate plus mefloquine, or dihydroartemisinin-piperaquine, or praziquantel control arm. The primary endpoints are efficacy (cure rate, assessed by microscopy) and safety (adverse events) of each study arm 6 weeks after treatment. Secondary endpoints include cumulative cure rate, egg reduction rate, and re-infection 12 weeks after treatment. The non-inferiority margin is set at - 10 for the risk difference in cure rates between praziquantel and the combined treatment. DISCUSSION: This study assesses a strategy for repurposing artemisinin-based combination therapies (ACTs) for treating schistosomiasis. It adopts a head-to-head comparison of four different ACTs to test a non-inferiority hypothesis and to strengthen local capacity to conduct clinical trials for interventions against neglected tropical diseases. TRIAL REGISTRATION: Pan-African Clinical Trials Registry PACTR202001919442161 . Retrospectively registered on 6 January 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Obonyo CO, Were VO, Wamae P, et al. SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection. Trials. 2023. PMID: 38012787. doi:10.1186/s13063-023-07790-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。